0001626199-24-000076.txt : 20240510
0001626199-24-000076.hdr.sgml : 20240510
20240510192652
ACCESSION NUMBER: 0001626199-24-000076
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240508
FILED AS OF DATE: 20240510
DATE AS OF CHANGE: 20240510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PENG STANFORD L
CENTRAL INDEX KEY: 0001711352
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37449
FILM NUMBER: 24936554
MAIL ADDRESS:
STREET 1: ALPINE IMMUNE SCIENCES, INC.
STREET 2: 188 EAST BLAINE STREET, SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC.
CENTRAL INDEX KEY: 0001626199
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 208969493
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-788-4545
MAIL ADDRESS:
STREET 1: 188 EAST BLAINE ST., SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Nivalis Therapeutics, Inc.
DATE OF NAME CHANGE: 20150211
FORMER COMPANY:
FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141121
4
1
wk-form4_1715383601.xml
FORM 4
X0508
4
2024-05-08
0
0001626199
ALPINE IMMUNE SCIENCES, INC.
ALPN
0001711352
PENG STANFORD L
C/O ALPINE IMMUNE SCIENCES, INC.
188 EAST BLAINE STREET, SUITE 200
SEATTLE
WA
98102
0
1
0
0
See Remarks
0
Common Stock
2024-05-08
4
M
0
7025
13.20
A
79396
D
Common Stock
2024-05-08
4
M
0
3126
6.51
A
82522
D
Common Stock
2024-05-08
4
M
0
37267
0.65
A
119789
D
Common Stock
2024-05-08
4
M
0
161492
0.65
A
281281
D
Common Stock
2024-05-08
4
M
0
22593
11.31
A
303874
D
Common Stock
2024-05-08
4
M
0
26912
3.23
A
330786
D
Common Stock
2024-05-08
4
M
0
13377
6.33
A
344163
D
Stock Option (Right to buy)
13.20
2024-05-08
4
M
0
7025
0
D
2031-01-04
Common Stock
7025
142975
D
Stock Option (Right to buy)
6.51
2024-05-08
4
M
0
3126
0
D
2029-02-05
Common Stock
3126
71874
D
Stock Option (Right to buy)
0.65
2024-05-08
4
M
0
37267
0
D
2027-03-13
Common Stock
37267
0
D
Stock Option (Right to buy)
0.65
2024-05-08
4
M
0
161492
0
D
2026-09-21
Common Stock
161492
0
D
Stock Option (Right to buy)
11.31
2024-05-08
4
M
0
22593
0
D
2028-01-01
Common Stock
22593
42407
D
Stock Option (Right to buy)
3.23
2024-05-08
4
M
0
26912
0
D
2030-01-22
Common Stock
26912
81088
D
Stock Option (Right to buy)
6.33
2024-05-08
4
M
0
13377
0
D
2028-09-27
Common Stock
13377
236623
D
Includes 48,000 shares of common stock underlying a restricted stock unit grant made on January 4, 2024.
The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person
continuing to be a service provider through each such date.
One-fourth (1/4) of the shares subject to the option will vest on February 6, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person
continuing to be a service provider through each such date.
One-fourth (1/4) of the shares subject to the option will vest on September 6, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person
continuing to be a service provider through each such date.
One-fourth (1/4) of the shares subject to the option will vest on January 2, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person
continuing to be a service provider through each such date.
One-fourth (1/4) of the shares subject to the option will vest on January 23, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person
continuing to be a service provider through each such date.
1/2 of the shares subject to the option become vested and exercisable on October 1, 2020 and the balance of the shares subject to the option become vested and exercisable on October 1, 2022, subject to continued service through each such date.
/s/ James Paul Rickey, attorney-in-fact
2024-05-10